Related Links Educational Materials About Clinical Trials Clinical Trials Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase II Study of GVAX Lung Cancer Vaccine in Patients With Selected Stage IIIB or Stage IV Bronchoalveolar Carcinoma

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase II	Treatment	Closed	Over 18	NCI	SWOG-S0310 S0310, NCT00074295

Trial Description

Purpose:

Vaccines made from a person's tumor tissue may make the body build an immune response to kill tumor cells.

This phase II trial is studying vaccine therapy to see how well it works in treating patients with stage IIIB or stage IV bronchoalveolar (lung) cancer.

Eligibility:

Eligibility criteria include the following:

• At least 19 years old
• More than 4 weeks since biological therapy, chemotherapy, or radiation therapy
• No previous gene therapy
• More than 2 weeks since steroid therapy
• More than 1 week since surgery
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients' tumor cells will be obtained and treated in the laboratory to make the vaccine. They will receive injections of the vaccine every 2 weeks for up to five vaccinations. Quality of life will be assessed periodically. Patients will be evaluated at 1 month, every 2 months for 1 year, and every 3 months for 2 years.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

Southwest Oncology Group

Angela Davies, MD, Study coordinator		Ph: 916-734-3771
Raja Mudad, MD, FACP, Study coordinator		Ph: 504-988-2967; 800-588-5300 Email: muda001@mailhost.tcs.tulane.edu

Registry Information
Official Title		Phase II Trial of CG8123, an Autologous Cancer Vaccine (GVAX), in Patients with Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC)
Trial Start Date		2004-03-01
Registered in ClinicalTrials.gov		NCT00074295
Date Submitted to PDQ		2003-11-04
Information Last Verified		2005-08-17
NCI Grant/Contract Number		U10-CA32102

Back to Top